Current Therapeutic Strategies for Inflammatory Bowel Disease: A Narrative Review
DOI:
https://doi.org/10.12775/QS.2026.74.76150Keywords
ibd, Crohn’s disease, ulcerative colitis, biological therapy, biological treatment, inflammatory bowel disease, TNF-alpha inhibitorsAbstract
Background: Inflammatory bowel disease (IBD) is a chronic, relapsing disorder resulting from genetic, immune, microbial, and environmental factors. Therapeutic options have expanded from conventional drugs to biologic agents and targeted small molecules, enabling individualized management.
Aim: This narrative review aimed to summarize current treatment strategies for IBD, focusing on conventional therapies, biologics, targeted small molecules, antibiotics, and surgery.
Materials and Methods: A narrative literature review was conducted using PubMed, MEDLINE, Google Scholar, and the Journal of Education, Health and Sport (JEHS). Current clinical guidelines, European Medicines Agency (EMA) product information, clinical studies, systematic reviews, and meta-analyses were reviewed, with attention to indications, efficacy, and safety.
Results: Biologic agents and targeted small molecules have broadened therapeutic options for moderate-to-severe IBD. Anti-TNF agents, vedolizumab, ustekinumab, selective IL-23 inhibitors, Janus kinase (JAK) inhibitors, and ozanimod act through different pathways and allow treatment to be adapted to disease phenotype, severity, and previous treatment exposure. Conventional therapies, including aminosalicylates, corticosteroids, thiopurines, and methotrexate, remain important in selected situations. Antibiotics retain a role in specific complications, while surgery remains essential in refractory disease and structural complications.
Conclusions: Contemporary IBD management follows an individualized, treat-to-target approach aimed at symptom control, objective inflammatory control, mucosal healing, and prevention of long-term complications. Despite therapeutic advances, uncertainties remain regarding treatment sequencing, predictors of response, long-term safety, and access to advanced therapies. Further research is needed to optimize personalized strategies and improve long-term outcomes.
References
1. Holko P, Kawalec P, Stawowczyk E. Prevalence and drug treatment practices of inflammatory bowel diseases in Poland in the years 2012-2014. Eur J Gastroenterol Hepatol. 2018;30(4):456-464. https://doi.org/10.1097/meg.0000000000001047
2. Baldassano RN, Piccoli DA. Inflammatory bowel disease in pediatric and adolescent patients. Gastroenterol Clin North Am. 1999;28(2):445-458. https://doi.org/10.1016/S0889-8553(05)70064-9 PMID: 10372276.
3. Tysk C, Lindberg E, Järnerot G, Flodérus-Myrhed B. Ulcerative colitis and Crohn's disease in an unselected population of monozygotic and dizygotic twins: a study of heritability and the influence of smoking. Gut. 1988;29(7):990-996. https://doi.org/10.1136/gut.29.7.990
4. Loftus EV Jr. Clinical epidemiology of inflammatory bowel disease: incidence, prevalence, and environmental influences. Gastroenterology. 2004;126(6):1504-1517. https://doi.org/10.1053/j.gastro.2004.01.063
5. Bager P, Simonsen J, Nielsen NM, Frisch M. Cesarean section and offspring's risk of inflammatory bowel disease: a national cohort study. Inflamm Bowel Dis. 2012;18(5):857-862. https://doi.org/10.1002/ibd.21805
6. Klement E, Cohen RV, Boxman J, Joseph A, Reif S. Breastfeeding and risk of inflammatory bowel disease: a systematic review with meta-analysis. Am J Clin Nutr. 2004;80(5):1342-1352. https://doi.org/10.1093/ajcn/80.5.1342
7. Hou JK, Abraham B, El-Serag H. Dietary intake and risk of developing inflammatory bowel disease: a systematic review of the literature. Am J Gastroenterol. 2011;106(4):563-573. https://doi.org/10.1038/ajg.2011.44
8. Shaw SY, Blanchard JF, Bernstein CN. Association between the use of antibiotics in the first year of life and pediatric inflammatory bowel disease. Am J Gastroenterol. 2010;105(12):2687-2692. https://doi.org/10.1038/ajg.2010.398
9. Knights D, Lassen KG, Xavier RJ. Advances in inflammatory bowel disease pathogenesis: linking host genetics and the microbiome. Gut. 2013;62(10):1505-1510. https://doi.org/10.1136/gutjnl-2012-303954
10. Gevers D, Kugathasan S, Denson LA, et al. The treatment-naive microbiome in new-onset Crohn's disease. Cell Host Microbe. 2014;15(3):382-392. https://doi.org/10.1016/j.chom.2014.02.005
11. Rosen MJ, Dhawan A, Saeed SA. Inflammatory bowel disease in children and adolescents. JAMA Pediatr. 2015;169(11):1053-1060. https://doi.org/10.1001/jamapediatrics.2015.1982
12. Bousvaros A, Antonioli DA, Colletti RB, et al. Differentiating ulcerative colitis from Crohn disease in children and young adults: report of a Working Group of the North American Society for Pediatric Gastroenterology, Hepatology, and Nutrition and the Crohn's and Colitis Foundation of America. J Pediatr Gastroenterol Nutr. 2007;44(5):653-674. . https://doi.org/10.1097/mpg.0b013e31805563f3
13. Kugathasan S, Judd RH, Hoffmann RG, et al.; Wisconsin Pediatric Inflammatory Bowel Disease Alliance. Epidemiologic and clinical characteristics of children with newly diagnosed inflammatory bowel disease in Wisconsin: a statewide population-based study. J Pediatr. 2003;143(4):525-531. https://doi.org/10.1067/S0022-3476(03)00444-X
14. Nahon S, Lahmek P, Lesgourgues B, et al. Diagnostic delay in a French cohort of Crohn’s disease patients. J Crohns Colitis. 2014;8(9):964-969. https://doi.org/10.1016/j.crohns.2014.01.023
15.Schoepfer AM, Dehlavi MA, Fournier N, et al. Diagnostic delay in Crohn's disease is associated with a complicated disease course and increased operation rate. Am J Gastroenterol. 2013;108(11):1744-1753. https://doi.org/10.1038/ajg.2013.248
16. Thia KT, Sandborn WJ, Harmsen WS, et al. Risk factors associated with progression to intestinal complications of Crohn’s disease in a population-based cohort. Gastroenterology. 2010;139(4):1147-1155. https://doi:10.1053/j.gastro.2010.06.070
17. Vavricka SR, Spigaglia SM, Rogler G, et al. Systematic evaluation of risk factors for diagnostic delay in inflammatory bowel disease. Inflamm Bowel Dis. 2012;18(3):496-505. https://doi:10.1002/ibd.21719
18. Peyrin-Biroulet L, Sandborn W, Sands BE, et al. Selecting therapeutic targets in inflammatory bowel disease (STRIDE): determining therapeutic goals for treat-to-target. Am J Gastroenterol. 2015;110(9):1324-1338. https://doi.org/10.1038/ajg.2015.233
19. Turner D, Ricciuto A, Lewis A, et al. STRIDE-II: an update on the Selecting Therapeutic Targets in Inflammatory Bowel Disease (STRIDE) Initiative of the International Organization for the Study of IBD (IOIBD): determining therapeutic goals for treat-to-target strategies in IBD. Gastroenterology. 2021;160(5):1570-1583. https://doi.org/10.1053/j.gastro.2020.12.031
20. Schoepfer AM, Beglinger C, Straumann A, et al. Fecal calprotectin correlates more closely with the Simple Endoscopic Score for Crohn’s disease (SES-CD) than CRP, blood leukocytes, and the CDAI. Am J Gastroenterol. 2010;105(1):162-169. https://doi:10.1038/ajg.2009.545
21. Boschetti G, Laidet M, Moussata D, et al. Levels of fecal calprotectin are associated with the severity of postoperative endoscopic recurrence in asymptomatic patients with Crohn’s disease. Am J Gastroenterol. 2015;110(6):865-872. https://doi.org/10.1038/ajg.2015.30
22. Klimczak K, Lykowska-Szuber L, Eder P, et al. The diagnostic usefulness of fecal lactoferrin in the assessment of Crohn’s disease activity. Eur J Intern Med. 2015;26(8):623-627. https://doi.org/10.1016/j.ejim.2015.06.015
23. Wright EK, Kamm MA, De Cruz P, et al. Measurement of fecal calprotectin improves monitoring and detection of recurrence of Crohn’s disease after surgery. Gastroenterology. 2015;148(5):938-947.e1. https://doi:10.1053/j.gastro.2015.01.026
24. Ferrante M, Colombel JF, Sandborn WJ, et al. Validation of endoscopic activity scores in patients with Crohn’s disease based on a post hoc analysis of data from SONIC. Gastroenterology.2013;145(5):978-986.e5. https://doi.org/10.1053/j.gastro.2013.08.010
25. Khanna R, Bressler B, Levesque BG, et al. Early combined immunosuppression for the management of Crohn’s disease (REACT): a cluster randomised controlled trial. Lancet.2015;386(10006):1825-1834. https://doi.org/10.1016/s0140-6736(15)00068-9
26. Colombel JF, Panaccione R, Bossuyt P, et al. Effect of tight control management on Crohn’s disease (CALM): a multicentre, randomised, controlled phase 3 trial. Lancet. 2017;390(10114):2779-2789. https://doi.org/10.1016/s0140-6736(17)32641-7
27. Maaser C, Sturm A, Vavricka SR, et al. ECCO-ESGAR Guideline for Diagnostic Assessment in IBD Part 1: Initial diagnosis, monitoring of known IBD, detection of complications. J Crohns Colitis. 2019;13(2):144-164. https://doi.org/10.1093/ecco-jcc/jjy113
28. Sandborn WJ, Hanauer S, Van Assche G, et al. Treating beyond symptoms with a view to improving patient outcomes in inflammatory bowel diseases. J Crohns Colitis. 2014;8(9):927-935. https://doi.org/10.1016/j.crohns.2014.02.021
29. Zallot C, Peyrin-Biroulet L. Deep remission in inflammatory bowel disease: looking beyond symptoms. Curr Gastroenterol Rep. 2013;15(3):315. https://doi.org/10.1007/s11894-013-0315-7
30. Baert F, Moortgat L, Van Assche G, et al. Mucosal healing predicts sustained clinical remission in patients with early-stage Crohn’s disease. Gastroenterology. 2010;138(2):463-468.e5. https://doi.org/10.1053/j.gastro.2009.09.056
31. Frøslie KF, Jahnsen J, Moum BA, Vatn MH; IBSEN Group. Mucosal healing in inflammatory bowel disease: results from a Norwegian population-based cohort. Gastroenterology. 2007;133(2):412-422. https://doi.org/10.1053/j.gastro.2007.05.051
32. Nuti F, Civitelli F, Bloise S, et al. Prospective evaluation of the achievement of mucosal healing with anti-TNF-α therapy in a paediatric Crohn’s disease cohort. J Crohns Colitis. 2016;10(1):5-12. https://doi.org/10.1093/ecco-jcc/jjv126
33. Lamb CA, Kennedy NA, Raine T, et al. British Society of Gastroenterology consensus guidelines on the management of inflammatory bowel disease in adults. Gut. 2019;68(Suppl 3):s1-s106. https://doi.org/10.1136/gutjnl-2019-318484
34. Rodemann JF, Dubberke ER, Reske KA, et al. Incidence of Clostridium difficile infection in inflammatory bowel disease. Clin Gastroenterol Hepatol. 2007;5(3):339-344. https://doi.org/10.1016/j.cgh.2006.12.027
35. Monaghan TM, Cockayne A, Mahida YR. Pathogenesis of Clostridium difficile infection and its potential role in inflammatory bowel disease. Inflamm Bowel Dis. 2015;21(8):1957-1966. https://doi.org/10.1097/mib.0000000000000461
36. Pascual V, Dieli-Crimi R, López-Palacios N, et al. Inflammatory bowel disease and celiac disease: overlaps and differences. World J Gastroenterol. 2014;20(17):4846-4856. https://doi.org/10.3748/wjg.v20.i17.4846
37. Bar Yehuda S, Axelrod R, Toker O, et al. The association of inflammatory bowel diseases with autoimmune disorders: a report from the epi-IIRN. J Crohns Colitis. 2019;13(3):324-329.https://doi.org/10.1093/ecco-jcc/jjy166
38. Le Baut G, O’Brien C, Pavli P, et al. Prevalence of Yersinia species in the ileum of Crohn’s disease patients and controls. Front Cell Infect Microbiol. 2018;8:336. https://doi.org/10.3389/fcimb.2018.00336
39. Hanada Y, Khanna S, Loftus EV Jr, et al. Non-Clostridium difficile bacterial infections are rare in patients with flares of inflammatory bowel disease. Clin Gastroenterol Hepatol. 2018;16(4):528-533. https://doi.org/10.1016/j.cgh.2017.10.008
40. Limsrivilai J, Lee CK, Prueksapanich P, et al. Validation of models using basic parameters to differentiate intestinal tuberculosis from Crohn’s disease: a multicenter study from Asia. PLoS One. 2020;15(11):e0242879. https://doi.org/10.1371/journal.pone.0242879
41. Dyson JK, Rutter MD. Colorectal cancer in inflammatory bowel disease: what is the real magnitude of the risk? World J Gastroenterol. 2012;18(29):3839-3848. https://doi.org/10.3748/wjg.v18.i29.3839
42. Benchimol EI, Seow CH, Steinhart AH, Griffiths AM. Traditional corticosteroids for induction of remission in Crohn’s disease. Cochrane Database Syst Rev. 2008;(2):CD006792. https://doi.org/10.1002/14651858.cd006792.pub2
43. Summers RW, Switz DM, Sessions JT Jr, et al. National Cooperative Crohn's Disease Study: results of drug treatment. Gastroenterology. 1979;77(4 Pt 2):847-869. Available from: https://pubmed.ncbi.nlm.nih.gov/38176/
44. Malchow H, Ewe K, Brandes JW, et al. European Cooperative Crohn's Disease Study (ECCDS): results of drug treatment. Gastroenterology. 1984;86(2):249-266. Available from: https://pubmed.ncbi.nlm.nih.gov/6140202/
45. Adamed Pharma SA. Encorton 1 mg, 5 mg, 10 mg, 20 mg tablets. Summary of Product Characteristics [Internet]. Pieńków (Poland): Adamed Pharma SA; [cited 2026 Jul 18]. Available from: https://leki.urpl.gov.pl/files/42_Encorton.pdf
46. Chande N, Townsend CM, Parker CE, MacDonald JK. Azathioprine or 6-mercaptopurine for induction of remission in Crohn’s disease. Cochrane Database Syst Rev. 2016;(10):CD000545. https://doi.org/10.1002/14651858.cd000545.pub5
47. Feagan BG, Rochon J, Fedorak RN, et al. Methotrexate for the treatment of Crohn’s disease. The North American Crohn’s Study Group Investigators. N Engl J Med. 1995;332(5):292-297. https://doi.org/10.1056/nejm199502023320503
48.. McDonald JWD, Wang Y, Tsoulis DJ, MacDonald JK, Feagan BG. Methotrexate for induction of remission in refractory Crohn’s disease. Cochrane Database Syst Rev. 2014;(8):CD003459. doi:10.1002/14651858.CD003459.pub3
49. Łodyga M, Eder P, Gawron-Kiszka M, et al. Guidelines for the management of patients with Crohn's disease. Recommendations of the Polish Society of Gastroenterology and the Polish National Consultant in Gastroenterology. Gastroenterol Rev. 2021;16(4):257-296. https://doi.org/10.5114/pg.2021.110914
50. Chhaya V, Saxena S, Cecil E, et al. Steroid dependency and trends in prescribing for inflammatory bowel disease: a 20-year national population-based study. Aliment Pharmacol Ther. 2016;44(5):482-494.https://doi.org/10.1111/apt.13700
51. Schoepfer AM, Bortolotti M, Pittet V, et al. The gap between scientific evidence and clinical practice: 5-aminosalicylates are frequently used for the treatment of Crohn’s disease. Aliment Pharmacol Ther. 2014;40(8):930-937. https://doi.org/10.1111/apt.12929
52. Ford AC, Kane SV, Khan KJ, et al. Efficacy of 5-aminosalicylates in Crohn’s disease: systematic review and meta-analysis. Am J Gastroenterol. 2011;106(4):617-629. https://doi.org/10.1038/ajg.2011.71
53. Rasmussen SN, Lauritsen K, Tage-Jensen U, et al. 5-Aminosalicylic acid in the treatment of Crohn’s disease: a 16-week double-blind, placebo-controlled, multicentre study with Pentasa. Scand J Gastroenterol. 1987;22(7):877-883. https://doi.org/10.3109/00365528708991929
54. Singleton JW, Hanauer SB, Gitnick GL, et al. Mesalamine capsules for the treatment of active Crohn’s disease: results of a 16-week trial. Pentasa Crohn’s Disease Study Group. Gastroenterology. 1993;104(5):1293-1301. https://doi.org/10.1016/0016-5085(93)90337-c
55. Tremaine WJ, Schroeder KW, Harrison JM, Zinsmeister AR. A randomized, double-blind, placebo-controlled trial of the oral mesalamine (5-ASA) preparation, Asacol, in the treatment of symptomatic Crohn’s colitis and ileocolitis. J Clin Gastroenterol. 1994;19(4):278-282. https://doi.org/10.1097/00004836-199412000-00003
56. Ferring Pharmaceuticals. PEACE study: a study with Pentasa in patients with active Crohn's disease [Internet]. ClinicalTrials.gov identifier: NCT00862121. 2012 [cited 2026 Jul 17]. Available from: https://clinicaltrials.gov/ct2/show/NCT00862121
57. Moja L, Danese S, Fiorino G, et al. Systematic review with network meta-analysis: comparative efficacy and safety of budesonide and mesalazine (mesalamine) for Crohn’s disease. Aliment Pharmacol Ther. 2015;41(11):1055-1065. https://doi.org/10.1111/apt.13190
58. Rezaie A, Kuenzig ME, Benchimol EI, et al. Budesonide for induction of remission in Crohn’s disease. Cochrane Database Syst Rev. 2015;(6):CD000296. https://doi.org/10.1002/14651858.cd000296.pub4
59. Akobeng AK, Zhang D, Gordon M, MacDonald JK. Oral 5-aminosalicylic acid for maintenance of medically-induced remission in Crohn’s disease. Cochrane Database Syst Rev. 2016;(9):CD003715. https://doi.org/10.1002/14651858.cd003715.pub3
60. Lim WC, Hanauer S. Aminosalicylates for induction of remission or response in Crohn’s disease. Cochrane Database Syst Rev. 2010;(12):CD008870. https://doi.org/10.1002/14651858.cd008870
61. Lim WC, Wang Y, MacDonald JK, Hanauer S. Aminosalicylates for induction of remission or response in Crohn’s disease. Cochrane Database Syst Rev. 2016;(7):CD008870. https://doi.org/10.1002/14651858.cd008870.pub2
62. Subramanian S, Ekbom A, Rhodes JM. Recent advances in clinical practice: a systematic review of isolated colonic Crohn’s disease: the third IBD? Gut. 2017;66(2):362-381. https://doi.org/10.1136/gutjnl-2016-312673
63. Hanauer SB, Strömberg U. Oral Pentasa in the treatment of active Crohn’s disease: a meta-analysis of double-blind, placebo-controlled trials. Clin Gastroenterol Hepatol. 2004;2(5):379-388. https://doi.org/10.1016/s1542-3565(04)00122-3
64. Coward S, Kuenzig ME, Hazlewood G, et al. Comparative effectiveness of mesalamine, sulfasalazine, corticosteroids, and budesonide for the induction of remission in Crohn’s disease: a Bayesian network meta-analysis. Inflamm Bowel Dis. 2017;23(2):E26-E37. https://doi.org/10.1097/mib.0000000000001023
65. Stidham RW, Lee TC, Higgins PDR, et al. Systematic review with network meta-analysis: the efficacy of anti-TNF agents for the treatment of Crohn’s disease. Aliment Pharmacol Ther. 2014;39(12):1349-1362. https://doi.org/10.1111/apt.12749
66. Sandborn WJ, Feagan BG, Rutgeerts P, et al. Vedolizumab as induction and maintenance therapy for Crohn’s disease. N Engl J Med. 2013;369(8):711-721. doi:10.1056/NEJMoa1215739. https://doi.org/10.1056/nejmoa1215739
67. Feagan BG, Sandborn WJ, Gasink C, et al. Ustekinumab as induction and maintenance therapy for Crohn’s disease. N Engl J Med. 2016;375(20):1946-1960. https://doi.org/10.1056/nejmoa1602773
68. Singh S, Fumery M, Sandborn WJ, Murad MH. Systematic review and network meta-analysis: first- and second-line biologic therapies for moderate-severe Crohn’s disease. Aliment Pharmacol Ther. 2018;48(4):394-409. https://doi.org/10.1111/apt.14852
69. Raine T, Bonovas S, Burisch J, et al. ECCO guidelines on therapeutics in ulcerative colitis: medical treatment. J Crohns Colitis. 2022;16(1):2-17. https://doi.org/10.1093/ecco-jcc/jjab178
70. Feuerstein JD, Isaacs KL, Schneider Y, et al. AGA clinical practice guidelines on the management of moderate to severe ulcerative colitis. Gastroenterology. 2020;158(5):1450-1461. https://doi.org/10.1053/j.gastro.2020.01.006
71. Harbord M, Eliakim R, Bettenworth D, et al. Third European Evidence-based Consensus on diagnosis and management of ulcerative colitis. Part 2: current management. J Crohns Colitis. 2017;11(7):769-784. https://doi.org/10.1093/ecco-jcc/jjx009
72. Sandborn WJ, Travis S, Moro L, et al. Once-daily budesonide MMX extended-release tablets induce remission in patients with mild to moderate ulcerative colitis: results from the CORE I study. Gastroenterology. 2012;143(5):1218-1226.e2. https://doi.org/10.1053/j.gastro.2012.08.003
73. Travis SP, Danese S, Kupcinskas L, et al. Once-daily budesonide MMX in active, mild-to-moderate ulcerative colitis: results from the randomised CORE II study. Gut. 2014;63(3):433-441. https://doi.org/10.1136/gutjnl-2012-304258
74. Rubin DT, Cohen RD, Sandborn WJ, et al. Budesonide multimatrix is efficacious for mesalamine-refractory, mild to moderate ulcerative colitis: a randomised, placebo-controlled trial. J Crohns Colitis. 2017;11(7):785-791. https://doi.org/10.1093/ecco-jcc/jjx032
75. Lennard-Jones JE, Longmore AJ, Newell AC, et al. An assessment of prednisone, salazopyrin, and topical hydrocortisone hemisuccinate used as out-patient treatment for ulcerative colitis. Gut. 1960;1:217-222. https://doi.org/10.1136/gut.1.3.217
76. Ford AC, Bernstein CN, Khan KJ, et al. Glucocorticosteroid therapy in inflammatory bowel disease: systematic review and meta-analysis. Am J Gastroenterol. 2011;106(4):590-599. https://doi.org/10.1038/ajg.2011.70
77. Rubin DT, Ananthakrishnan AN, Siegel CA, Sauer BG, Long MD. ACG Clinical Guideline: ulcerative colitis in adults. Am J Gastroenterol. 2019;114(3):384-413. https://doi.org/10.14309/ajg.0000000000000152
78. Dinesen LC, Walsh AJ, Protic MN, et al. The pattern and outcome of acute severe colitis. J Crohns Colitis. 2010;4(4):431-437. https://doi.org/10.1016/j.crohns.2010.02.001
79. Bojic D, Radojicic Z, Nedeljkovic-Protic M, et al. Long-term outcome after admission for acute severe ulcerative colitis in Oxford: the 1992-1993 cohort. Inflamm Bowel Dis. 2009;15(6):823-828. https://doi.org/10.1002/ibd.20843
80. Travis SP, Farrant JM, Ricketts C, et al. Predicting outcome in severe ulcerative colitis. Gut. 1996;38(6):905-910. https://doi.org/10.1136/gut.38.6.905
81. Dassopoulos T, Cohen RD, Scherl EJ, et al. Ulcerative colitis care pathway. Gastroenterology. 2015;149(1):238-245. https://doi.org/10.1053/j.gastro.2015.05.036
82. Eder P, Łodyga M, Gawron-Kiszka M, et al. Guidelines for the management of ulcerative colitis. Recommendations of the Polish Society of Gastroenterology and the Polish National Consultant in Gastroenterology. Gastroenterology Rev 2023; 18 (1): 1–42. DOI: https://doi.org/10.5114/pg.2023.125882
83. Borrelli O, Cordischi L, Cirulli M, et al. Polymeric diet alone versus corticosteroids in the treatment of active pediatric Crohn's disease: a randomized controlled open-label trial. Clin Gastroenterol Hepatol. 2006;4(6):744-753. https://doi.org/10.1016/j.cgh.2006.03.010
84. Critch J, Day AS, Otley A, et al. Use of enteral nutrition for the control of intestinal inflammation in pediatric Crohn disease. J Pediatr Gastroenterol Nutr. 2012;54(2):298-305. https://doi.org/10.1097/mpg.0b013e318235b397
85. Feagan BG, Macdonald JK. Oral 5-aminosalicylic acid for induction of remission in ulcerative colitis. Cochrane Database Syst Rev. 2012;(10):CD000543. https://doi.org/10.1002/14651858.cd000543.pub3
86. Zeisler B, Lerer T, Markowitz J, et al. Outcome following aminosalicylate therapy in children newly diagnosed as having ulcerative colitis. J Pediatr Gastroenterol Nutr. 2013;56(1):12-18. https://doi.org/10.1097/mpg.0b013e31826ac41a
87. Astellas Pharma Sp. z o.o. Asamax 250 mg, Asamax 500 mg gastro-resistant tablets. Summary of Product Characteristics [Internet]. Warsaw (Poland): Astellas Pharma Sp. z o.o.; [cited 2026 Jul 18]. Available from: https://rejestrymedyczne.ezdrowie.gov.pl/api/rpl/medicinal-products/12779/characteristic
88. Markowitz J, Grancher K, Kohn N, Lesser M, Daum F. A multicenter trial of 6-mercaptopurine and prednisone in children with newly diagnosed Crohn's disease. Gastroenterology. 2000;119(4):895-902. https://doi.org/10.1053/gast.2000.18144
89. Dulai PS, Thompson KD, Blunt HB, Dubinsky MC, Siegel CA. Risks of serious infection or lymphoma with anti-tumor necrosis factor therapy for pediatric inflammatory bowel disease: a systematic review. Clin Gastroenterol Hepatol. 2014;12(9):1443-1451. https://doi.org/10.1016/j.cgh.2014.01.021
90. Turner D, Grossman AB, Rosh J, et al. Methotrexate following unsuccessful thiopurine therapy in pediatric Crohn's disease. Am J Gastroenterol. 2007;102(12):2804-2812. https://doi.org/10.1111/j.1572-0241.2007.01474.x
91. European Medicines Agency. Jylamvo (methotrexate): summary of product characteristics [Internet]. 2026 [cited 2026 Jul 12]. Available from: https://www.ema.europa.eu/en/medicines/human/EPAR/jylamvo
92. Selinger CP, Rosiou K, Lenti MV. Biological therapy for inflammatory bowel disease: cyclical rather than lifelong treatment? BMJ Open Gastroenterol. 2024;11(1):e001225. https://doi.org/10.1136/bmjgast-2023-001225
93. Vulliemoz M, Brand S, Juillerat P, Mottet C, Ben-Horin S, Michetti P; on on behalf of Swiss IBDnet, an official working group of the Swiss Society of Gastroenterology. TNF-alpha blockers in inflammatory bowel diseases: practical recommendations and a user's guide: an update. Digestion. 2020;101(Suppl 1):16-26. https://doi.org/10.1159/000506898
94. Verstockt B, Salas A, Sands BE, Abraham C, Leibovitzh H, Neurath MF, Vande Casteele N; Alimentiv Translational Research Consortium (ATRC). IL-12 and IL-23 pathway inhibition in inflammatory bowel disease. Nat Rev Gastroenterol Hepatol. 2023;20(7):433-446. https://doi.org/10.1038/s41575-023-00768-1
95. Colombel JF, Sandborn WJ, Reinisch W, et al.; SONIC Study Group. Infliximab, azathioprine, or combination therapy for Crohn's disease. N Engl J Med. 2010;362(15):1383-1395. https://doi.org/10.1056/NEJMoa0904492
96. Panaccione R, Ghosh S, Middleton S, et al. Combination therapy with infliximab and azathioprine is superior to monotherapy with either agent in ulcerative colitis. Gastroenterology. 2014;146(2):392-400.e3. https://doi.org/10.1053/j.gastro.2013.10.052
97. Ruder B, Atreya R, Becker C. Tumour necrosis factor alpha in intestinal homeostasis and gut related diseases. Int J Mol Sci. 2019;20(8):1887. https://doi.org/10.3390/ijms20081887
98. European Medicines Agency. Remicade (infliximab): summary of product characteristics [Internet]. 2026 [cited 2026 Jul 12]. Available from: https://www.ema.europa.eu/en/medicines/human/EPAR/remicade
99. European Medicines Agency. Humira (adalimumab): summary of product characteristics [Internet]. 2026 [cited 2026 Jul 12]. Available from: https://www.ema.europa.eu/en/medicines/human/EPAR/humira
100. European Medicines Agency. Simponi (golimumab): summary of product characteristics [Internet]. 2026 [cited 2026 Jul 12]. Available from: https://www.ema.europa.eu/en/medicines/human/EPAR/simponi
101. Łodyga M, Eder P, Bartnik W, et al. New pharmaceuticals in inflammatory bowel disease. Prz Gastroenterol. 2015;10(2):57-60. https://doi.org/10.5114/pg.2015.52702
102. European Medicines Agency. Cimzia (certolizumab pegol): summary of product characteristics [Internet]. 2026 [cited 2026 Jul 12]. Available from: https://www.ema.europa.eu/en/medicines/human/EPAR/cimzia-0
103. Yamazaki H, So R, Matsuoka K, et al. Certolizumab pegol for induction of remission in Crohn's disease. Cochrane Database Syst Rev. 2019;(8):CD012893. https://doi.org/10.1002/14651858.CD012893.pub2
104. European Medicines Agency. Entyvio (vedolizumab): summary of product characteristics [Internet]. 2026 [cited 2026 Jul 12]. Available from: https://www.ema.europa.eu/en/medicines/human/EPAR/cimzia-0
105. European Medicines Agency. Stelara (ustekinumab): summary of product characteristics [Internet]. 2026 [cited 2026 Jul 12]. Available from: https://www.ema.europa.eu/en/medicines/human/EPAR/stelara
106. Puca P, Parello S, Colantuono S, et al. Interleukin-23 inhibitors in inflammatory bowel disease. BioDrugs. 2026;40(3):479-492. https://doi.org/10.1007/s40259-026-00781-1
107. Pool IA, Otten AT, Kosterink JGW, Dijkstra G, Mian P, Bourgonje AR. Interleukin-23p19 inhibitors in inflammatory bowel disease: from current insights to future directions. J Pers Med. 2026;16(2):119. https://doi.org/10.3390/jpm16020119
108. Wu H, Zhou Y, Chen X, Wang L, Guo Y, Du X, Miao X. Safety and efficacy of different JAK inhibitors in the treatment of inflammatory bowel disease: a network meta-analysis. Front Pharmacol. 2026;16:1699928. https://doi.org/10.3389/fphar.2025.1699928
109. European Medicines Agency. Rinvog (upadacitinib): summary of product characteristics [Internet]. 2026 [cited 2026 Jul 14]. Available from: https://www.ema.europa.eu/en/medicines/human/EPAR/rinvoq
110. European Medicines Agency. Xeljanz (tofacitinib): summary of product characteristics [Internet]. 2026 [cited 2026 Jul 14]. Available from: https://www.ema.europa.eu/en/medicines/human/EPAR/xeljanz
111. European Medicines Agency. Jyseleca (filgotinib): summary of product characteristics [Internet]. 2026 [cited 2026 Jul 14]. Available from: https://www.ema.europa.eu/en/medicines/human/EPAR/jyseleca
112. Choi Y, Lee S, Kim HJ, Park T, Kwack WG, Yang S, Chung EK. State-of-the-art evidence for clinical outcomes and therapeutic implications of Janus kinase inhibitors in moderate-to-severe ulcerative colitis: a narrative review. Pharmaceuticals (Basel). 2025;18(5):740. https://doi.org/10.3390/ph18050740
113. European Medicines Agency. Zeposia (ozanimod): summary of product characteristics [Internet]. 2026 [cited 2026 Jul 15]. Available from: https://www.ema.europa.eu/en/medicines/human/EPAR/zeposia
114. Sandborn WJ, Feagan BG, D'Haens G, et al.; True North Study Group. Ozanimod as induction and maintenance therapy for ulcerative colitis. N Engl J Med. 2021;385(14):1280-1291. https://doi.org/10.1056/NEJMoa2033617
115. Nitzan O, Elias M, Peretz A, Saliba W. Role of antibiotics for treatment of inflammatory bowel disease. World J Gastroenterol. 2016;22(3):1078-1087. https://doi.org/10.3748/wjg.v22.i3.1078
116. Tocia C, Dumitru IM, Alexandrescu L, Petcu LC, Dumitru E. Does rifaximin offer any promise in Crohn's disease in remission and concurrent irritable bowel syndrome-like symptoms? Medicine (Baltimore). 2021;100(1):e24059. https://doi.org/10.1097/MD.0000000000024059
117. Spinelli A, Bonovas S, Burisch J, et al. ECCO guidelines on therapeutics in ulcerative colitis: surgical treatment. J Crohns Colitis. 2022;16(2):179-189. https://doi.org/10.1093/ecco-jcc/jjab177
118. Magro F, Gionchetti P, Eliakim R, et al. Third European Evidence-based Consensus on diagnosis and management of ulcerative colitis. Part 1: definitions, diagnosis, extra-intestinal manifestations, pregnancy, cancer surveillance, surgery, and ileo-anal pouch disorders. J Crohns Colitis. 2017;11(6):649-670. https://doi.org/10.1093/ecco-jcc/jjx008
119. Tomasik M, Warzyszak P, Małek R, et al. Ulcerative colitis – recent and potential methods of treatment: review. J Educ Health Sport. 2023;13(3):65-73. https://doi.org/10.12775/JEHS.2023.13.03.009
120. Adamina M, Bonovas S, Raine T, et al. ECCO guidelines on therapeutics in Crohn’s disease: surgical treatment. J Crohns Colitis. 2020;14(2):155-168. https://doi.org/10.1093/ecco-jcc/jjz187
121. Navaneethan U, Lourdusamy V, Njei B, Shen B. Endoscopic balloon dilation in the management of strictures in Crohn’s disease: a systematic review and meta-analysis of non-randomized trials. Surg Endosc. 2016;30(12):5434-5443. https://doi.org/10.1007/s00464-016-4902-1
122. Yamamoto T, Fazio VW, Tekkis PP. Safety and efficacy of strictureplasty for Crohn’s disease: a systematic review and meta-analysis. Dis Colon Rectum. 2007;50(11):1968-1986. https://doi.org/10.1007/s10350-007-0279-5
123. Torres J, Bonovas S, Doherty G, et al. ECCO guidelines on therapeutics in Crohn’s disease: medical treatment. J Crohns Colitis. 2020;14(1):4-22. https://doi.org/10.1093/ecco-jcc/jjz180
124. Panés J, García-Olmo D, Van Assche G, et al. Long-term efficacy and safety of stem cell therapy (Cx601) for complex perianal fistulas in patients with Crohn’s disease. Gastroenterology. 2018;154(5):1334-1342.e4. https://doi.org/10.1053/j.gastro.2017.12.020
125. Panés J, García-Olmo D, Van Assche G, et al. Expanded allogeneic adipose-derived mesenchymal stem cells (Cx601) for complex perianal fistulas in Crohn’s disease: a phase 3 randomised, double-blind controlled trial. Lancet. 2016;388(10051):1281-1290. https://doi.org/10.1016/S0140-6736(16)31203-X
126. Van Assche G, Dignass A, Reinisch W, et al. The second European evidence-based Consensus on the diagnosis and management of Crohn’s disease: special situations. J Crohns Colitis. 2010;4(1):63-101. doi:10.1016/j.crohns.2009.09.009. https://doi.org/10.1016/j.crohns.2009.09.009
127. Gionchetti P, Dignass A, Danese S, et al. 3rd European Evidence-based Consensus on the Diagnosis and Management of Crohn’s Disease 2016: Part 2: Surgical Management and Special Situations. J Crohns Colitis. 2017;11(2):135-149. https://doi.org/10.1093/ecco-jcc/jjw169
Downloads
Published
How to Cite
Issue
Section
License
Copyright (c) 2026 Anna Zyskowska, Bartosz Seroczyński, Julia Beata Woźniak, Jakub Marcel Korowicki, Marta Labon, Milena Dziedzina, Wiktoria Karolina Nowak, Andrzej GU, Helena Strzelka
This work is licensed under a Creative Commons Attribution-NonCommercial-ShareAlike 4.0 International License.
Stats
Number of views and downloads: 21
Number of citations: 0
